Open access
Aug 2026
Novel Intranasal Influenza-Vectored Vaccine Corfluvec Provides Protection Against Influenza and COVID-19, Mitigating SARS-CoV-2-Induced Lung Vascular Damage
Its ability to limit viral shedding from the upper respiratory tract and to mitigate SARS-CoV-2-induced pulmonary pathology, contributing to the preservation of lung vascular integrity, underscores the utility of mucosal immunization with Corfluvec as a valuable intranasal complement to current systemic vaccination strategies.
M. Stukova, A. Shurygina, Arman Muzhikyan et al.
· Vaccines · 0 citations